About Cassiopea
Cassiopea is a company based in Lainate (Italy) founded in 2009 was acquired by Cosmo Pharmaceuticals in October 2021. The company has 653 employees. Cassiopea operates in a competitive market with competitors including Revance Therapeutics, Dermavant, Sol-Gel Technologies, SkinMedica and Hugel, among others.
- Headquarter Lainate, Italy
- Employees 653
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cassiopea.com
- Social LinkedIn X YouTube
- Acquired by Cosmo Pharmaceuticals (Oct 2021)
- Legal Name Electronic Arts Games (India) Private Limited
- Date of Incorporation 28 Jul, 2004
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹656 Cr
FY 2025 · +19% YoY
- Net Profit₹74.14 Cr
FY 2025 · 11% margin
- EBITDA₹198 Cr
FY 2025 · 30% margin
- Investors
- Employee Count653
- Acquired byCosmo Pharmaceuticals
(Oct 2021)
Associated legal entities of Cassiopea
Cassiopea operates through Electronic Arts Games (India) Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Electronic Arts Games (India) Private Limited CIN U72900TG2004PTC043773 | Active | 28 Jul 2004 | Hyderabad, Telangana | ₹656 Cr | 653 | 3 | View details |
Investors in Cassiopea
Cassiopea has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cosmo Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapeutics for gastrointestinal diseases are developed and provided. | 1996 | cosmopharma.com | Dublin, Ireland |
Investor details for Cassiopea
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Electronic Arts Games (India) Private Limited (Cassiopea)
Electronic Arts Games (India) Private Limited is the primary company behind Cassiopea. The board of Electronic Arts Games (India) Private Limited currently have 3 directors; the longest-serving is Priya Krishnadas, appointed in 2020. 16 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Priya Krishnadas DIN 08760418 | Managing Director | 02 Jul 2020 | 6 yrs 3 mo | Electronic Arts Games (India) Private Limited |
| Yong Soo Bae DIN 09327082 | Director | 09 Feb 2022 | 4 yrs 8 mo | Electronic Arts Games (India) Private Limited |
| James Larbey Crane DIN 11202254 | Director | 12 Sep 2025 | 1 yr | Electronic Arts Games (India) Private Limited |
Financials of Cassiopea
Figures of Electronic Arts Games (India) Private Limited, the primary company behind Cassiopea, for FY 2025. Revenue was ₹656 Cr (+19% year on year). Net profit was ₹74.14 Cr (11% margin). EBITDA was ₹198 Cr (30% margin). Revenue has grown at a compounded annual rate of +45% over three years and +37% over five years.
- ₹656 CrRevenue · FY 2025 · +19% YoY
- ₹74.14 CrNet profit · 11% margin
- ₹198 CrEBITDA · 30% margin
- ₹1.7 LakhPaid-up capital
- 653Employees (provident fund records)
- +45%Revenue CAGR, 3 years
- +37%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Electronic Arts Games (India) Private Limited are on its company page.
Detailed financial statements for Cassiopea
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Cassiopea
2 dated milestones of Cassiopea across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Cassiopea is founded.
- Exit Acquired by Cosmo Pharmaceuticals.
Competitors of Cassiopea
Cassiopea operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Dermavant, Sol-Gel Technologies, SkinMedica and Hugel, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| dermavant.com | 2016 | Phoenix, United States | $160M | – | Small molecule therapeutics for inflammatory skin diseases are developed. | |
| sol-gel.com | 1998 | United States | $9M | – | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. | |
| skinmedica.com | 1999 | Carlsbad, United States | $94.24M | – | Skin care products are developed and manufactured by SkinMedica. | |
| hugel.co.kr | 2001 | Chuncheon-si, South Korea | – | – | Therapeutics in aesthetics are developed, including botulinum toxin products. | |
| biofrontera.com | 1997 | Leverkusen, Germany | – | 149 | Solutions for dermatological therapeutics and consumer products are provided. | |
| collplant.com | 2004 | Ness Ziona, Israel | $16.3M | – | Plant-derived collagen is developed for tissue repair and 3D bioprinting. | |
| sofregen.com | 2014 | Medford, United States | $17.8M | 8 | Silk-derived biomaterials are developed for soft tissue repair in surgery. | |
| dermatarx.com | 2014 | San Diego, United States | $15.67M | 8 | Therapeutics for dermatologic and ophthalmologic diseases are developed. | |
| histogen.com | 2007 | San Diego, United States | $51.4M | 22 | Regenerative medicine is developed using embryonic cell alternatives. |
Detailed competitors of Cassiopea
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cassiopea
The website of Cassiopea (cassiopea.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▲ 20.6% vs previous month
Latest news on Cassiopea
Complete news archive for Cassiopea
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cassiopea
10 companies that operate in the same segment as Cassiopea (Dermatology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Developer of drugs for treating dermatology diseases | 1908 | Copenhagen, Denmark | USD 560.38 M | – | – | |
Skincare, beauty, and wellness services provided by VLCC across multiple countries. | 1989 | Delhi, Delhi, India | – | – | – | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608 M | – | – | |
Immunotherapeutic solutions for dermatological conditions are developed. | 2016 | Westlake Village, California, United States | USD 94.5 M | USD 376.07 M | 342 | |
Targeted small molecules are developed for oncology treatments. | 2010 | Singapore, Singapore | USD 100 M | – | – | |
Pharmaceutical formulations for dermatology, gastroenterology, and wellness are manufactured. | 2014 | Pune, Maharashtra, India | USD 25.97 M | USD 18.15 M | 508 | |
Novel dermatologic therapies are developed for skin conditions. | 2012 | Malvern, Pennsylvania, United States | USD 82 M | USD 7.83 M | 64 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cassiopea
Cassiopea was founded in 2009.
Cassiopea is headquartered in Lainate, Italy. It is registered at Lainate, Lombardy, Italy.
Cassiopea has 653 employees.
The primary company behind Cassiopea, Electronic Arts Games (India) Private Limited, reported revenue of ₹656 Cr for FY 2025, up 19% year on year.
Cassiopea, founded in 2009 and based in Lainate, Italy, operates as a clinical-stage pharmaceutical company specializing in dermatology. Topical treatments for acne, androgenic alopecia, and genital warts are targeted through four drug candidates: Winlevi in Phase III for acne, Breezula in Phase II for alopecia, another for acne in Phase II, and one for HPV in Phase I. The company was renamed from Cosmo Dermatos in April 2015.
Cassiopea's top competitors include Revance Therapeutics, Dermavant and Collplant.
Cassiopea has 1 investor. Key investors include Cosmo Pharmaceuticals.
Cassiopea operates through Electronic Arts Games (India) Private Limited.
Yes. Cassiopea was acquired by Cosmo Pharmaceuticals in October 2021.
The legal entities of Cassiopea currently have 3 directors, including Priya Krishnadas, Yong Soo Bae, James Larbey Crane.